1.14
Rani Therapeutics Holdings Inc stock is traded at $1.14, with a volume of 847.43K.
It is up +7.55% in the last 24 hours and down -15.56% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$1.06
Open:
$1.08
24h Volume:
847.43K
Relative Volume:
0.72
Market Cap:
$111.21M
Revenue:
$1.20M
Net Income/Loss:
$-47.60M
P/E Ratio:
-1.4418
EPS:
-0.7907
Net Cash Flow:
$-27.78M
1W Performance:
-4.20%
1M Performance:
-15.56%
6M Performance:
+137.90%
1Y Performance:
-20.83%
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RANI
Rani Therapeutics Holdings Inc
|
1.14 | 103.40M | 1.20M | -47.60M | -27.78M | -0.7907 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - Bitget
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - The Manila Times
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Drive Corporate and Pipeline Development - Quiver Quantitative
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - GlobeNewswire Inc.
Rani Therapeutics Holdings Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Rani Therapeutics (RANI) Expected to Announce Earnings on Monday - MarketBeat
If You Invested $1,000 in Rani Therapeutics Holdings, Inc. (RANI) - Stock Titan
US Market Recap: Will Rani Therapeutics Holdings Inc outperform during market ralliesFed Meeting & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: Will Rani Therapeutics Holdings Inc outperform during market ralliesTrade Risk Assessment & Real-Time Stock Entry Alerts - baoquankhu1.vn
Volatility Watch: Can Rani Therapeutics Holdings Inc beat the S P 5002026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
Published on: 2026-03-21 04:57:56 - baoquankhu1.vn
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Rani Therapeutics Holdings Inc (RANI) - MSN
Aug Momentum: Can Rani Therapeutics Holdings Inc navigate macro headwinds2026 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rani Therapeutics Hldgs (RANI) Stock Analysis Report | Financials & Insights - Benzinga Japan
RANI Stock Price, Quote & Chart | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
US Market Wrap: Will Rani Therapeutics Holdings Inc outperform during market rallies2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
What is the next catalyst for Rani Therapeutics Holdings Inc2026 Market WrapUp & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Maxim Group Keeps Their Buy Rating on Rani Therapeutics Holdings (RANI) - The Globe and Mail
What is Rani Therapeutics Holdings Incs revenue forecastTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Rani Therapeutics Holdings, Inc.Class A Common Stock (Nasdaq:RANI) Stock Quote - The Chronicle-Journal
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
RANIRani Therapeutics Holdings, Inc. Latest Stock News & Market Updates - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bank Watch: What dividend growth rate does Deswell Industries Inc offerTrend Reversal & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc. reach all time highs this year2025 Market WrapUp & Verified Momentum Watchlists - mfd.ru
Will Rani Therapeutics Holdings Inc. stock outperform growth indexesWeekly Investment Report & High Accuracy Trade Signal Alerts - mfd.ru
Published on: 2026-02-20 14:00:46 - baoquankhu1.vn
Published on: 2026-02-20 04:36:50 - baoquankhu1.vn
Rani Therapeutics (NASDAQ:RANI) Trading 1.6% HigherTime to Buy? - MarketBeat
RANI Should I Buy - Intellectia AI
Will Rani Therapeutics Holdings Inc. outperform during market rallies2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Does Rani Therapeutics Holdings Inc. offer margin of safety2025 Year in Review & Safe Investment Capital Preservation Plans - mfd.ru
Investment firm reports 9.9% stake in Rani Therapeutics (RANI) - Stock Titan
Published on: 2026-02-13 18:32:35 - baoquankhu1.vn
SymBiosis Capital takes 6.5% passive stake in Rani Therapeutics (RANI) Class A - Stock Titan
Is Rani Therapeutics Holdings Inc. stock near bottom after decline2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Income Plays: What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Published on: 2026-02-02 11:44:32 - baoquankhu1.vn
Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit - simplywall.st
Vanguard discloses 5.23% Rani Therapeutics (RANI) stake in Schedule 13G - Stock Titan
Rani Therapeutics promotes Alireza Javadi to chief technical officer By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. Announces Promotion of Alireza Javadi to Chief Technical Officer - marketscreener.com
Rani Therapeutics announces the promotion of Alireza Javadi, Ph.D. to chief technical officer - marketscreener.com
Rani Therapeutics Names Alireza Javadi Chief Technical Officer - Nasdaq
Rani Therapeutics promotes Alireza Javadi to chief technical officer - Investing.com
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - The Manila Times
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):